NCT01822561View on ClinicalTrials.gov

Eplerenone for Central Serous Chorioretinopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

April 30, 2017

Study Completion Date

December 31, 2017

Conditions
Central Serous Chorioretinopathy
Interventions
DRUG

Eplerenone 50mg

All patients will receive the same dose of eplerenone.

Trial Locations (1)

02111

New England Eye Center / Tufts Medical Center, Boston

All Listed Sponsors
lead

Tufts Medical Center

OTHER

NCT01822561 - Eplerenone for Central Serous Chorioretinopathy | Biotech Hunter | Biotech Hunter